Compare Occidental Petroleum Corporation (OXY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Occidental Petroleum Corporation trades at $60.12 (market cap $60.26B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.1× Occidental Petroleum Corporation's market cap, and Occidental Petroleum Corporation pays a 1.86% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Occidental Petroleum Corporation for 92 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| OXY | VRTX | |
|---|---|---|
Market Cap | $60.26B | $127.55B |
Volume | 11,718,920 | 1,487,944 |
Sector | Energy | Health |
52-Week High | $66.24 | $557.96 |
52-Week Low | $38.92 | $407.37 |
Typical Hold Time | 92 Days | 120 Days |
Enterprise Value | $79.02B | $121.68B |
Dividend Yield | 1.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $60.11, up 3.26% with strong technical momentum and bullish moving averages. The company demonstrates robust profitability with 30.32% net margin and 21.46% ROE, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Recent earnings beats and a $71.40 consensus price target suggest upside potential, supported by Goldman Sachs' October 2026 upgrade citing debt reduction and cash flow targets.
OXY presents a compelling value case with attractive valuation multiples (P/E 17.78, EV/EBITDA 5.56) and strong analyst support (52% buy ratings). Key risks include oil price volatility and declining revenue trends, while catalysts include Q3 2026 earnings on November 9 and continued execution on the $4B cash flow target. The stock's technical positioning near resistance at $61 requires monitoring for breakout confirmation.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
